Peringatan Keamanan

Data regarding acute overdoses of glucocorticoids are rare.L13203 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.A188405 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.A188405

Cortisone acetate

DB01380

small molecule approved investigational

Deskripsi

Cortisone acetate was first isolate in 1935 and became more widely researched in 1949.A226295 Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, and gastrointestinal diseases and disorders.A226300,L13203

Cortisone acetate was granted FDA approval on 13 June 1950.L15107

Struktur Molekul 2D

Berat 402.4807
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) Data regarding the clearance of cortisone acetate is not readily available.[L13203]

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Corticosteroids are eliminated predominantly in the urine.A187436

Interaksi Makanan

1 Data
  • 1. Take with food. Taking cortisone acetate with food may reduce gastrointestinal upset.

Interaksi Obat

1240 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Cortisone acetate.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cortisone acetate.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cortisone acetate.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Cortisone acetate.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cortisone acetate.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Cortisone acetate.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Cortisone acetate.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cortisone acetate.
Pegaspargase The serum concentration of Cortisone acetate can be increased when it is combined with Pegaspargase.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cortisone acetate.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cortisone acetate.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Cortisone acetate.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Cortisone acetate.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Cortisone acetate.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cortisone acetate.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Cortisone acetate.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cortisone acetate.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Cortisone acetate.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Cortisone acetate.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cortisone acetate.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cortisone acetate.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Cortisone acetate.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cortisone acetate.
Cladribine Cortisone acetate may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Cortisone acetate.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Cortisone acetate.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Cortisone acetate.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Cortisone acetate.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Cortisone acetate.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Cortisone acetate.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Cortisone acetate.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Cortisone acetate.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Cortisone acetate.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cortisone acetate.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Cortisone acetate.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Cortisone acetate.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Cortisone acetate.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Cortisone acetate.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Cortisone acetate.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Cortisone acetate.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Cortisone acetate.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Cortisone acetate.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Cortisone acetate.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Cortisone acetate.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Cortisone acetate.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Cortisone acetate.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Cortisone acetate.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Cortisone acetate.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Cortisone acetate.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Cortisone acetate.
Tretinoin The metabolism of Tretinoin can be increased when combined with Cortisone acetate.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Cortisone acetate.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Cortisone acetate.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Cortisone acetate.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Cortisone acetate.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Cortisone acetate.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Cortisone acetate.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Cortisone acetate.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Cortisone acetate.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cortisone acetate.
Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Cortisone acetate.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Cortisone acetate.
Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Cortisone acetate.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Cortisone acetate.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Cortisone acetate.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Cortisone acetate.
Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Cortisone acetate.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Cortisone acetate.
Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Cortisone acetate.
Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Cortisone acetate.
Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Cortisone acetate.
Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Cortisone acetate.
Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Cortisone acetate.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Cortisone acetate.
Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Cortisone acetate.
Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Cortisone acetate.
Stepronin The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Stepronin.
Hydroxychloroquine The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Hydroxychloroquine.
Castanospermine The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Castanospermine.
Vorinostat The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Vorinostat.
2-Methoxyethanol The risk or severity of adverse effects can be increased when Cortisone acetate is combined with 2-Methoxyethanol.
Brequinar The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Brequinar.
Pirfenidone The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Pirfenidone.
Interferon alfa The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Interferon alfa.
Glatiramer The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Glatiramer.
Briakinumab The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Briakinumab.
Human interferon omega-1 The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Human interferon omega-1.
Mepolizumab The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Mepolizumab.
Abetimus The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Abetimus.
Belatacept The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Belatacept.
Bendamustine The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Bendamustine.
Pralatrexate The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Pralatrexate.
Wortmannin The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Wortmannin.
Eribulin The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Eribulin.
Belimumab The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Belimumab.
Teriflunomide The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Teriflunomide.
Carfilzomib The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Carfilzomib.
Dimethyl fumarate The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Dimethyl fumarate.
Obinutuzumab The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Obinutuzumab.
Vedolizumab The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Vedolizumab.

Target Protein

Steroid hormone receptor ERR2 ESRRB
Estrogen-related receptor gamma ESRRG
Glucocorticoid receptor NR3C1
Steroid hormone receptor ERR1 ESRRA
Annexin A1 ANXA1

Referensi & Sumber

Synthesis reference: Reichstein,T.; US. Patent 2,403,683; July 9, 1946. Gallagher,T.F.; US. Patent 2,447,325; August 17,1948; assigned to Research Corporation. Sarett, L.H.; U.S. Patent 2,541,104; February 13, 1951; assigned to Merck & Co., Inc.
Artikel (PubMed)
  • PMID: 18140647
    BOLAND EW, HEADLEY NE: Effects of cortisone acetate on rheumatoid arthritis. J Am Med Assoc. 1949 Oct 1;141(5):301-8. doi: 10.1001/jama.1949.02910050001001.
  • PMID: 32034322
    Hardy RS, Raza K, Cooper MS: Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat Rev Rheumatol. 2020 Mar;16(3):133-144. doi: 10.1038/s41584-020-0371-y. Epub 2020 Feb 7.
  • PMID: 30285357
    Yasir M, Sonthalia S: Corticosteroid Adverse Effects .
  • PMID: 15634032
    Czock D, Keller F, Rasche FM, Haussler U: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003.
  • PMID: 23300763
    Gardill BR, Vogl MR, Lin HY, Hammond GL, Muller YA: Corticosteroid-binding globulin: structure-function implications from species differences. PLoS One. 2012;7(12):e52759. doi: 10.1371/journal.pone.0052759. Epub 2012 Dec 26.
  • PMID: 24347992
    Ciriaco M, Ventrice P, Russo G, Scicchitano M, Mazzitello G, Scicchitano F, Russo E: Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother. 2013 Dec;4(Suppl 1):S94-8. doi: 10.4103/0976-500X.120975.

Contoh Produk & Brand

Produk: 11 • International brands: 1
Produk
  • Cortisone Acetate
    Tablet • 5 mg/1 • Oral • US • Approved
  • Cortisone Acetate
    Tablet • 10 mg/1 • Oral • US • Approved
  • Cortisone Acetate
    Tablet • 25 mg/1 • Oral • US • Generic • Approved
  • Cortisone Acetate
    Tablet • 25 mg/1 • Oral • US • Generic • Approved
  • Cortisone Acetate
    Tablet • 25 mg/1 • Oral • US • Generic • Approved
  • Cortisone Acetate
    Tablet • 25 mg/1 • Oral • US • Generic • Approved
  • Cortisone Acetate
    Tablet • 25 mg • Oral • Canada • Approved
  • Cortisone Acetate
    Tablet • 25 mg/1 • Oral • US • Generic • Approved
Menampilkan 8 dari 11 produk.
International Brands
  • Cortisyl

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul